3-Amino-6-chloro-2-hydroxy-benzamide | 454471-70-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Amino-6-chloro-2-hydroxy-benzamide
• 英文别名: 6-Chloro-2-hydroxy-3-aminobenzamide；3-amino-6-chloro-2-hydroxybenzamide
• CAS: 454471-70-6
• 化学式: C₇H₇ClN₂O₂
• 分子量: 186.598
• InChiKey: ZUGBXAMVNYSFEJ-UHFFFAOYSA-N

物化性质

• 沸点：
  299.8±40.0 °C(Predicted)
• 密度：
  1.544±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  89.3
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Amino-6-chloro-2-hydroxy-benzamide 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 6-Chloro-3-(3,4-dioxo-2-(phenylamino)cyclobut-1-enylamino)-2-hydroxybenzamide
  参考文献：
  名称：

  Comparison of N,N′-diarylsquaramides and N,N′-diarylureas as antagonists of the CXCR2 chemokine receptor

  摘要：

  N,N'-diarylsquaramides were prepared and evaluated as antagonists of CXCR2. The compounds were found to be potent and selective antagonists of CXCR2. Significant differences in SAR was observed relative to the previously described N,N'-diarylurea series. As was the case in the N,N'-diarylurea series, placing sulfonamide substituent adjacent to the acidic phenol significantly reduced the clearance in rat pharmacokinetic studies. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.067
• 作为产物：
  描述：

  2,6-dichloro-3-nitrobenzoic acid amide 在 platinum on activated charcoal 水 、 氢气 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 生成 3-Amino-6-chloro-2-hydroxy-benzamide
  参考文献：
  名称：

  Comparison of N,N′-diarylsquaramides and N,N′-diarylureas as antagonists of the CXCR2 chemokine receptor

  摘要：

  N,N'-diarylsquaramides were prepared and evaluated as antagonists of CXCR2. The compounds were found to be potent and selective antagonists of CXCR2. Significant differences in SAR was observed relative to the previously described N,N'-diarylurea series. As was the case in the N,N'-diarylurea series, placing sulfonamide substituent adjacent to the acidic phenol significantly reduced the clearance in rat pharmacokinetic studies. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.067

文献信息

• BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
  申请人：Chu Daniel

  公开号：US20090197863A1

  公开（公告）日：2009-08-06

  A compound having the structure set forth in Formula (I) or Formula (II): wherein the variables Y, R 1 , R 2 , R 3 , and R 4 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

  具有以下式(I)或式(II)所示结构的化合物： 其中变量Y，R1，R2，R3和R4如本文所定义。本文提供了聚(ADP-核糖)聚合酶活性的抑制剂。本文还描述了包括至少一种本文描述的化合物的药物组合物，以及使用本文描述的化合物或药物组合物治疗通过抑制PARP活性改善的疾病、疾病和症状。
• Il-8 receptor antagonists
  申请人：——

  公开号：US20040132694A1

  公开（公告）日：2004-07-08

  This invention relates to the novel use of amide squaramides in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

  本发明涉及酰胺并四氢喹啉酰胺在治疗由趋化因子白细胞介素-8（IL-8）介导的疾病状态中的新用途。
• IL-8 receptor antagonists
  申请人：Palovich R. Michael

  公开号：US20060084661A1

  公开（公告）日：2006-04-20

  This invention relates to the novel use of amide squaramides in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

  本发明涉及酰胺方酰胺在治疗由趋化因子Interleukin-8（IL-8）介导的疾病状态中的新用途。
• Discovery of potent and orally bioavailable N,N′-diarylurea antagonists for the CXCR2 chemokine receptor
  作者：Qi Jin、Hong Nie、Brent W. McCleland、Katherine L. Widdowson、Michael R. Palovich、John D. Elliott、Richard M. Goodman、Miriam Burman、Henry M. Sarau、Keith W. Ward、Melanie Nord、Bonnie M. Orr、Peter D. Gorycki、Jakob Busch-Petersen

  DOI：10.1016/j.bmcl.2004.06.097

  日期：2004.9

  A series of 3-substituted N,N'-diarylureas was prepared and the structure-activity relationship relative to CXCR2 receptor affinity as well as their pharmacokinetic properties were examined. In vitro microsomal metabolism studies indicated that the lower clearance rates of the 3-sulfonamido-substituted compounds were most likely due to the suppression of glucuronidation. (C) 2004 Elsevier Ltd. All rights reserved.
• EP1357909A4
  申请人：——

  公开号：EP1357909A4

  公开（公告）日：2006-01-04